|
|
|
- るるみ うえや
- 5 years ago
- Views:
Transcription
1
2 BC BC
3 569 (A.D.) Marium Varius Variola 910 (A.D.) Al-Razi Razi * Pediatr Inf Dis J 1999; 18:85-93
4 400 (A.D.)
5 568 Elephant
6 18
7 Marcus Aurelius Pediatr Inf Dis J 1999; 18:85-93
8 Variolation (Variolation)
9 10 * Uvularia grandiflora * Fenner et al. Smallpox and its Eradication. p252
10 1798, (Cowpox) Cowpox) Variolae Vaccinae Variolae Vaccinae * Pediatr Inf Dis J 1999; 18:85-93
11 1796
12 Sarah Nelmes Sarah Nelmes
13 982 Variolation Inoculation Haygarth 1793
14 Variolation Variolation Variolation Variolation % CFR CFR Variolation Variolation CFR CFR
15 Vaccination 1940 Collier * Henderson DA, Moss M, Smallpox and Vaccinia in Vaccines, 3 rd edition, 1999
16 1945
17 98%
18 * Dowdle WR, Hopkins DR, The Eradication of Infectious Diseases, John Wiley & Sons, Chichester pp47-59
19 Pan American Sanitary Organization Henderson DA, Moss B, Smallpox and Vaccinia in Vaccines, 3 rd edition, 1999
20 1967 Henderson DA, Moss B, Smallpox and Vaccinia in Vaccines, 3 rd edition, 1999
21 1967 Endemic
22 Henderson DA, Moss B, Smallpox and Vaccinia in Vaccines, 3 rd edition, 1999
23
24
25 (Mass Vaccination)
26 *4 Modified from Epid Rev 1993;15: , Am J Prev Med 2001; 20 (4S): , MMWR 2000; 49 (SS-9); R o %* 83-94% 75-86% 92-94% 94% 80-86% 86% 83-85% 85% 80-85% 85% 83%* 92% 92% 83%* 90% 92% % 96% 97% 97% 97% 97%
27 6 7 N-95
28 % in Fenner F et al. Smallpox and its Eradication, pp200
29 Bull WHO 1975; 52: Gerere Gerere N Game Game
30 Am J Epidemiology 1974; 99:
31 26/ / /65 96% 4% 12% From Mack et al, Summarized in Fenner et al. Smallpox and its eradication, pg 688
32 > % 45% 0% 10.5% 0.7% 13.9% 3.7% 54.2% 5.5% 50.0% From Outbreak in Liverpool, England, In Fenner F et al. Smallpox and its Eradication, pp53
33 >20 52% 29% 1.4% 7% 11% In Fenner F et al. Smallpox and its Eradication, pp53
34
35 29.5% 47.6% in Fenner F et al. Smallpox and its Eradication, pp 591
36 3, 1,000 1, st and 2nd visit, 1-2 days apart Am J Epidemiolgy 1974; 99:
37
38 Heiner et al Amer J Epidemiol 1971; 91: (N) (N) AR (%)
39 400,000
40
41 Kuralia, Bhola
42 ** Rahima Banu Ali Maow Maalin **
43
44 1980
45 Ken Alibek 1980 JAMA 1999; 281:
46
›Áfi¡ŒÎ“F’æ’¶
Shigetaka KATOW 2002 12 13 2 CDC Centers for Disease Control and Prevention CDC TV Dr. Julie L. Gerberding CDC 1 2001 9 11 2001 7 3 2 TV 60 2009 2 1 3 50 30 1976 1 5 BC1157 1 DNA DNA RNA 0100-0006 - -
% ORG/WIKI/FILE:SALKWS.JPG 1. ORG/WIKI
3 3.1 世界的なポリオ根絶 67 3, 7 8 1789 19 19 198 55. 8. HTTP://WWW. POLIOERADICATION.ORG/ POLIOANDPREVENTION. ASPX 1931 19511233 1949 3 55 7. HTTP://UPLOAD.WIKIMEDIA.ORG/WIKIPEDIA/ COMMONS/5/5C/POLIO_EGYPTIAN_STELE.JPG.
第122号.indd
-1- -2- -3- 0852-36-5150 0852-36-5163-4- -5- -6- -7- 1st 1-1 1-2 1-3 1-4 1-5 -8- 2nd M2 E2 D2 J2 C2-9- 3rd M3 E3 D3 J3 C3-10- 4th M4 E4 D4 J4 C4-11- -12- M5 E5 J5 D5 C5 5th -13- -14- NEWS NEWS -15- NEWS
234 50cm
234 50cm () 1 10 2 3 4 1 5 6 2 2 1 7 ( ー ) っ ー っ 8 1 2 10 10 2m 4m 6m 15m 457-2472 585-1154 9 10 2 60 2 100 RC SRC 30 80 500 1 500 500 ) 10 B b A 2 A B 2m 457-2473 585-1154 11 20m a 2m 3 3 1m 75cm 120cm
untitled
c OR 21 OR 1. 21 21 IoT OR OR OR 260 8672 1 8 1 OR 2. 2.1 public health [1] communicable (infectious) diseases vehicle burden HIV/AIDS (SARS) 258 60 Copyright c by ORSJ. Unauthorized reproduction of this
Microsoft Word - 01マニュアル・入稿原稿p1-112.doc
4 54 55 56 ( ( 1994 1st stage 2nd stage 2012 57 / 58 365 46.6 120 365 40.4 120 13.0 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 4 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
H27 28 4 1 11,353 45 14 10 120 27 90 26 78 323 401 27 11,120 D A BC 11,120 H27 33 H26 38 H27 35 40 126,154 129,125 130,000 150,000 5,961 11,996 6,000 15,000 688,684 708,924 700,000 750,000 1300 H28
RX501NC_LTE Mobile Router取説.indb
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 1 2 3 4 5 6 7 8 19 20 21 22 1 1 23 1 24 25 1 1 26 A 1 B C 27 D 1 E F 28 1 29 1 A A 30 31 2 A B C D E F 32 G 2 H A B C D 33 E 2 F 34 A B C D 2 E 35 2 A B C D 36
日経テレコン料金表（2016年4月）
1 2 3 4 8,000 15,000 22,000 29,000 5 6 7 8 36,000 42,000 48,000 54,000 9 10 20 30 60,000 66,000 126,000 166,000 50 100 246,000 396,000 1 25 8,000 7,000 620 2150 6,000 4,000 51100 101200 3,000 1,000 201
73 p.1 22 16 2004p.152
1987 p.80 72 73 p.1 22 16 2004p.152 281895 1930 1931 12 28 1930 10 27 12 134 74 75 10 27 47.6 1910 1925 10 10 76 10 11 12 139 p.287 p.10 11 pp.3-4 1917 p.284 77 78 10 13 10 p.6 1936 79 15 15 30 80 pp.499-501
122011pp.139174 18501933
122011pp.139174 18501933 122011 1850 3 187912 3 1850 8 1933 84 4 1871 12 1879 5 2 1 9 15 1 1 5 3 3 3 6 19 9 9 6 28 7 7 4 1140 9 4 3 5750 58 4 3 1 57 2 122011 3 4 134,500,000 4,020,000 11,600,000 5 2 678.00m
2 2 3 4 5 5 2 7 3 4 6 1 3 4 7 4 2 2 2 4 2 3 3 4 5 1932 A p. 40. 1893 A p. 224, p. 226. 1893 B pp. 1 2. p. 3.
1 73 72 1 1844 11 9 1844 12 18 5 1916 1 11 72 1 73 2 1862 3 1870 2 1862 6 1873 1 3 4 3 4 7 2 3 4 5 3 5 4 2007 p. 117. 2 2 3 4 5 5 2 7 3 4 6 1 3 4 7 4 2 2 2 4 2 3 3 4 5 1932 A p. 40. 1893 A p. 224, p. 226.
29 2011 3 4 1 19 5 2 21 6 21 2 21 7 2 23 21 8 21 1 20 21 1 22 20 p.61 21 1 21 21 1 23
29 2011 3 pp.55 86 19 1886 2 13 1 1 21 1888 1 13 2 3,500 3 5 5 50 4 1959 6 p.241 21 1 13 2 p.14 1988 p.2 21 1 15 29 2011 3 4 1 19 5 2 21 6 21 2 21 7 2 23 21 8 21 1 20 21 1 22 20 p.61 21 1 21 21 1 23 1
Microsoft Word - 映画『東京裁判』を観て.doc
1 2 3 4 5 6 7 1 2008. 2 2010, 3 2010. p.1 4 2008 p.202 5 2008. p.228 6 2011. 7 / 2008. pp.3-4 1 8 1 9 10 11 8 2008, p.7 9 2011. p.41 10.51 11 2009. p. 2 12 13 14 12 2008. p.4 13 2008, p.7-8 14 2008. p.126
() L () 20 1
() 25 1 10 1 0 0 0 1 2 3 4 5 6 2 3 4 9308510 4432193 L () 20 1 PP 200,000 P13P14 3 0123456 12345 1234561 2 4 5 6 25 1 10 7 1 8 10 / L 10 9 10 11 () ( ) TEL 23 12 7 38 13 14 15 16 17 18 L 19 20 1000123456
308 ( ) p.121
307 1944 1 1920 1995 2 3 4 5 308 ( ) p.121 309 10 12 310 6 7 ( ) ( ) ( ) 50 311 p.120 p.142 ( ) ( ) p.117 p.124 p.118 312 8 p.125 313 p.121 p.122 p.126 p.128 p.156 p.119 p.122 314 p.153 9 315 p.142 p.153
戦後の補欠選挙
1 2 11 3 4, 1968, p.429., pp.140-141. 76 2005.12 20 14 5 2110 25 6 22 7 25 8 4919 9 22 10 11 12 13 58154 14 15 1447 79 2042 21 79 2243 25100 113 2211 71 113 113 29 p.85 2005.12 77 16 29 12 10 10 17 18
![.V...z.\](/thumbs/40/20575037.jpg ".V...z.\")
学術フロンティア推進事業プロジェクト研究シリーズ １２
1 2 1 1983 pp.2136. 2. 1978.Leo Kanner 1973 Childhood Psychosis: Initial Studies and New Insight ; John Wiley & Sons, Inc. 5 6 7 3 1985 8 9 10 3 11 4 RGR 1992 Robert Horner et al. 1988 Generalization and
1 1.1 ワクチンの定義 Variolae vaccinae 1798 1 1. A B b Hib 2 1 4 2012 1. 2012 5 2. 1 1 13 bb 3 B b 3. 6 2012 1 3 23 1.2 4 3 A B DTaP Tdap bhib 2 HPV H1N1 3. 2 AS04 A MF59 2 2. 1... http://www.fda.gov/biologicsbloodvaccines/safetyavailability/vaccinesafety/ucm096228#t2
00_Cover.pmd
SS-100/200/300/500 14443 Rev. A 1-1 1-1 1-2 2-1 2-2 3-1 3-2 3-3 3-4 4 1 2 3 7 5 6 2 3 4 5 6 1 7 2 8 3 9 4 10 5 11 6 12 1 7 3-5 S E 3 KIV 3.5mm 2 x4 KIV 2.0mm 2 x2 E 3 KIV 2.0mm 2 x1 M 7 1 2 3 4 5 6 M
07-第4章村上英吾.indd
1990 1990 2007 2000 2007 9 3 46 1 2 1960 1 1984 60 3 1970 4 2000 2003 2009 2011 12007 2 2007 12 25 2 1 2007 10 19 1 5 2007 12 11 3 Bradshaw, J., et. al., 2008. 41982 47 2010 5 2011 2004 2004 1994 5 2009
109
108 1 2 3 109 110 111 112 1 c c < c c< B N a d 1 2 3 5 8 9 0 ; 2c< rc a h 3c 113 1p 2c< 3c< a r 4cc 1p 2 c 3c< c p a c 4p 5 c rr c c Cr m e 114 1 c c < c< B N d a 1 3 5 9 0 ; 2c< B ; p c< BN50; ar h 3c
42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =
![42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =](/thumbs/73/68712188.jpg "42 3 u = (37) MeV/c 2 (3.4) [1] u amu m p m n [1] m H [2] m p = (4) MeV/c 2 = (13) u m n = (4) MeV/c 2 =")
3 3.1 3.1.1 kg m s J = kg m 2 s 2 MeV MeV [1] 1MeV=1 6 ev = 1.62 176 462 (63) 1 13 J (3.1) [1] 1MeV/c 2 =1.782 661 731 (7) 1 3 kg (3.2) c =1 MeV (atomic mass unit) 12 C u = 1 12 M(12 C) (3.3) 41 42 3 u
_??_ Fig. 1. Annual number of subjects who were bitten by possibly rabid animals in the rabies endemic regions and thereafter visited our vaccine clin
_??_ Fig. 1. Annual number of subjects who were bitten by possibly rabid animals in the rabies endemic regions and thereafter visited our vaccine clinic to receive the rabies post-exposure prophylaxis.
本組よこ／根間：文１１－１１＿Ｐ１３１－１５８
131 132 pp 133 134 a b 135 S pp S 136 a p b p S 137 p S p p H a p b 138 p H p p 139 T T pp pp a b c S a Sp a 140 b c d Sp a b c d e Spp a 141 b c d S a b c d S pp a b 142 c d e S S S S S S S 143 S S S
Taro10-名張１審無罪判決.PDF
-------------------------------------------------------------------------------- -------------------------------------------------------------------------------- -1- 39 12 23 36 4 11 36 47 15 5 13 14318-2-
Message from SENDENKAIGI
AD Advertisement course for job hunting Message from SENDENKAIGI SPORT Messages for students FASHION CSR TOKYOGIRLSCOLLECTIONbygirlswalker.com2008SPRING/SUMMER About SENDENKAIGI About the course About
…h…L…–…†…fi…g1
RY RO RR RW LN LM LB LC MH MG MB RD RM RG LD CW SB VR BB EB PW PY PP PG PB 0 contents WR LR MR BR DR PM SM MC CB BO 0 P P7 P P5 P9 P 0 P4 P48 P54 P60 P66 P 04 RY RO RR RW RD RM RG LN LM LB LC LD MH MG
2006
2006.11.25 92 1869 H 92 U 19 1895 X 1896. 20 92 X X 1 ev DNA ev DNA DNA 300 28 JCO 1999 9 JCO DNA 1934 66 X X 15 40 2 2.4 3 BEIR-VII 0.01 50 50 0.5 100 0.5 5000 30 1.6 2.25 2.25 1000 0.2 0.1 2000 10 245
SBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
2 21 211,,, (Hz), AM (1MHz), 300m, 24 (245GHz), 12cm, 212 (electromagnetic fields), (electromagnetic radiations) (NIR),X,,,, RF, ELF,,, 22 221,, 2005
1 2003 6 7500 2 1 1 1 WHO, IARC, 2004 2 1973 1993 16 1997 SAR 2002 6, SAR 2W/kg, WHO ICNIRP 2 21 211,,, (Hz), AM (1MHz), 300m, 24 (245GHz), 12cm, 212 (electromagnetic fields), (electromagnetic radiations)
日本皮膚科学会雑誌第121巻第14号
World J Surg Burns Burns JTrauma Lancet Lancet Surg Gynecol Obste J Burn Care Rehabil BMJ Pediatr Emerg Care The Treatment of Burns Burns, A Team Approach Surg Gynecol Obstet NEnglJMed J Burn Care Rehabil
neutrino
Fermion 1st 2nd 3rd Quark Lepton aaacc3icbvdlsgmxfm34rpvvdekmwarbldmiqluig5cvhfvojcwt3mldm8mqzjqy9apc+ctuxki49qfc+temj4w2hkg4nhmuyt1rypk2rvvtzm0vlc4tf1akq2vrg5ulre1bltnfwaess9wiiabobpiggq6nvafjig71qhc59ov3odst4sb0uwgt0heszpqyk7vkzyedxtpdq5ssdzjfhxjujuwdretlgchamlapt+koggejnyflnegtvfok2pjmcqhdodg66bmpcxoidkmcbsug05as2imdafoqsai6zefldpc+vdo4lsoeyfbi/t2rk0trfhlzzejmv097q/e/r5mz+czmmugza4koh4ozjo3ew2zwmymghvctivqx+1dmu0qramx/rvucn73ylpgpk+cv7/qkxl2ytffau2gphsapnaiquki15cokhtezekvvzppz4rw7h+pondoz2uf/4hz+abswmfi=
2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
Global Commission for the Certification of the Eradication of Poliomyelitis GCC 1 Global action plan for laboratory containment of wild polio
55 pp.161 178 2005 WHO 2 2 WHO global action plan for laboratory containment of wild polioviruses (Second edition) SARS WHO BSL biosafety level CNS central nervous system GCC Global Commission for the
h4_1_et
1 RY RO RM RG RR RW RD LN LM LB LC LD MW MG MB CW SB VR BB EB WR LR MR BR DR PM SM MC CB BO 2 3 RY RO RR RW RD RM RG LN LM LB LC LD MW MG MB 4 CW SB VR BB EB 5 PI PY PP PG PB 6 WR LR MR BR DR 7 SM MC CB
11月/庵原俊昭
Shigetaka KATOW 2001 10 Kandahar BC 330 Alexander 1 al-iskandar Iskandar 74 Alexandria Arachosiorum 100km 2 BC323 6 10 2 6 18 28 1 1 BC333 Bucephalus.. http:upload.wikimedia.org wikipedia commons a ac
2009.2.28 3 83 2 16050kgBMI19.5 6 PG 200g/300kcal 1247,560 7 8 9 3 12 9 3 12 A B C D E F G 83 M M M M M M M A 83 M B M C M D M E M F M G M A 83 M B M C M D M E M F M G M A 83 M B M C M D M E M F M
4) H. Takayama et al.: J. Med. Chem., 45, 1949 (2002). 5) H. Takayama et al.: J. Am. Chem. Soc., 112, 8635 (2000). 6) H. Takayama et al.: Tetrahedron Lett., 42, 2995 (2001). 9) M. Kitajima et al: Chem.
5) Corn meal Agar Corn meal @ 40 Agar @ 20 6) Corn Meal Blood Agar 7) Agar 8) Blood Agar Saccharide @ 30.0 NaNO3 @ 2.0 K2HPO4 @ 1.0 MgSO47H2O @ 0.5 KC1 @ 0.5 F2SO47H2O @ 0.01 Agar @ 30.0 11) Mueller Hinton
がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性
2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Power Transformation and Its Modifications Toshimitsu HAMASAKI, Tatsuya ISOMURA, Megu OHTAKI and Masashi GOTO Key words : identity transformation, pow
Power Transformation and Its Modifications Toshimitsu HAMASAKI, Tatsuya ISOMURA, Megu OHTAKI and Masashi GOTO Key words : identity transformation, power-normal distribution, structured data, unstructured
_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
The Heart Healthy Tocotrienol Complex Tocomin SupraBio
The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation
Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS BPD CHD 50mg100mg RS20138 RS Respiratory Syncytial Virus RS
RS Synagis RS RSRespiratory Syncytial Virus RSBPD CHDRS RS RS1998 7020021BPD 200510CHD 50mg100mg2012 812 RS20138 RS Respiratory Syncytial Virus RS 28 12 29 35 6 6BPD24 24CHD 24 24 28 2935 RS 12 6 RS BPD
13●53頁●６－７▲院内感染対策▲.ppt
No.610 1 No.121 2 No.128 Nosocomial infection, Hospital-acquired infection CDC nosocomial infection, hospital-acquired infection nosocomial nosokomeion hospital nosocomial infection nosocomial pneumonia
Taro13-学習ノート表紙.PDF
10 11 12 13 13 14 15 18 22 27 30 32 A B C -1- -2- 1 2 A BC -3- -4- A B C -5- A B C -6- A B C -7- -8- 1-1 1-6 1-2 6-1 1-5 1-3 2-1 6-6 6-2 1-4 2-6 2-2 6-5 6-3 2-5 2-3 6-4 2-4 5-1 3-1 5-6 5-2 3-6 3-2 5-5
P15 P211 1 P1 P4 P2 P3 P4 P17
P15 P211 1 P1 P4 P2 P3 P4 P17 P3 P4 P7 P8 P9 2 1 Q A P17 P17 1 2 3 4 3 5 6 7 8 2 P17 Q A P17 4 1 2 3 4 2 P17 P4 P12 P17 P4 5 5 6 7 8 2 P4 P4 6 1 2 3 4 3 P17 P10 P17 7 5 6 7 8 4 0120-096-991 P17 8 1 2 3
140 120 100 80 60 40 20 0 115 107 102 99 95 97 95 97 98 100 64 72 37 60 50 53 50 36 32 18 H18 H19 H20 H21 H22 H23 H24 H25 H26 H27 1 100 () 80 60 40 20 0 1 19 16 10 11 6 8 9 5 10 35 76 83 73 68 46 44 H11
Mantel-Haenszelの方法
Mantel-Haenszel 2008 6 12 ) 2008 6 12 1 / 39 Mantel & Haenzel 1959) Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Nat. Cancer Inst. 1959; 224):
4 2 p = p(t, g) (1) r = r(t, g) (2) p r t g p r dp dt = p dg t + p g (3) dt dr dt = r dg t + r g dt 3 p t p g dt p t 3 2 4 r t = 3 4 2 Benefit view dp
( ) 62 1 1 47 2 3 47 2 e-mail:miyazaki@ngu.ac.jp 1 2000 2005 1 4 2 p = p(t, g) (1) r = r(t, g) (2) p r t g p r dp dt = p dg t + p g (3) dt dr dt = r dg t + r g dt 3 p t p g dt p t 3 2 4 r t = 3 4 2 Benefit
™·”õ/sec3_p63_84/fiü“eflÅ
Section3 64 1 65 Section 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 Babara E. Ainsworth et al. Med. Sci. Sports. Exevc.1993 66 67 Section 3 1 10 9 8 1 2 3 4 7 6 5 6 7 5 1 2 3 4 68 69 Section 3 2 70 Section 3
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
FAO Animal Health Manual No
FAO Animal Health Manual No. 16 FMD A. EMPRES FAO EMPRES FAO 17 1 2005 PREPARATION OF FOOT-AND-MOUTH DISEASE CONTINGENCY PLANS William A. Geering: Consultant, ENPRES/Infectious Diseases Group, FAO, Rome;
idwr2008_21
VanC 521 0.63 0.24 2.12 2.27 1.07 0.98 1.75 0.70 27.24 0.76 1.16 0.35 1.26 0.71 2SD 1SD 1SD 2SD A SD 0.21 0.58 3.02 7.02 1.89 0.70 0.20 0.72 0.11 0.37 0.43 0.04 0.79 0.39 5515 6.19 Streptococcus pyogenes
48 皮 膚 第29巻 第1号 昭 和62年2月 第1-b図 第1-a図 第1図Micro Trak法 アッ 皮 細 胞 中あ るいは細 pin point sizeの による 胞 外に,アッ 粒子と 直 接 塗 抹 標本から プル グ リ ー ン に光 プル し てelelnentary る 粒子
Chlamydia trachomatis-syphilis-micro Trak Mariko SEISHIMA, M. D., Satoshi OKUMURA, M. D. and Michihiro OHTANI, M. D. Megumi WATANABE, Ph. D., Ryo MATSUMOTO, Ph. D., Masayoshi TSUTSUMI, Ph. D. and Kazumasa
エンゲルス『イギリスにおける労働階級の状態』
The Condition of the Working Class in England *1 * 2 2015 6 17 *1 1844-45, 1887 *2 c 2014 4.0 (http:// creativecommons.org/licenses/by/4.0/) i (1845) http://bit.ly/mxet23 ii (1845) 1845 3 15 iii http://bit.ly/n77oug
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
Structure and Strength of Acid-Base in Aqueous Medium Aritsune KAJI* and Masaru NAKAHARA* * Department of Chemistry, Faculty of Science, Kyoto Univers
Structure and Strength of Acid-Base in Aqueous Medium Aritsune KAJI* and Masaru NAKAHARA* * Department of Chemistry, Faculty of Science, Kyoto University 1) J. Hayami, N. Ono, A. Kaji, Tetrahedron
pg. 2
pg. 1 pg. 2 pg. 3 pg. 4 pg. 5 pg. 6 pg. 7 pg. 8 pg. 9 pg. 10 pg. 11 pg. 12 pg. 13 pg. 14 pg. 15 pg. 16 pg. 17 pg. 18 pg. 19 pg. 20 pg. 21 2010-4-8 pg. 22 Answer2010-4-8 pg. 23 pg. 24 Answer2010-4-8 Answer2010-4-8
産衛誌57-4たより.indb
A89 26 7 1 9 4 33 1 87 A90 24 A91 23 ACOH2014 A92 4 1 2 3 4 5 6 7 A93 A94 A95 A96 A97 A98 A99 A100 A101 27 8 1 9 A102 4 33 A103 A104 26 3 140 27 1 A105 27 A106 A107 A108 A109 A110 A111 A112 A113 et al
経済論集 ４６‐２（よこ）（Ｐ）☆／２．三崎
1 2 1869 11 17 5 10 1 3 1914 5 15 5 1872 9 12 3 1870 1 26 14 1881 11 11 12 6 11 1878 5 9 13 1880 6 17 1 15 1882 1 2 3 11 1828 2 26 24 1891 4 22 2 1849 12 1 3 1856 pp 20 21. 1971 p.429. 1973 1, pp.440 444.
3 4 6 7 8 9 10 12 14 2 3
3 4 6 7 8 9 10 12 14 2 3 POINT 4 5 3053 1323 4 7 6 1 1 4 7 Yamada N. et al : Int J Cardiol. 98, 409-411, 2005 6 7 POINT 0 20 40 60 80 100 60 80 Ota M. et al: Heart Vessels. 17, 7-11,2002 40 60 20 50 15
2 3 5 5 5 5 6 6 7 7 8 10 10 10 10 11 11 12 12 13 16 16 16 16 17 19 21 21 22 5
1D000425-2 1 2 3 5 5 5 5 6 6 7 7 8 10 10 10 10 11 11 12 12 13 16 16 16 16 17 19 21 21 22 5 3 29 29 29 30 31 31 32 35 35 35 36 41 41 41 46 48 48 48 52 57 4 700 13 1988 4 5 4 5 21 1 1 3 4 5 6 21 10 1888